Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease

NCT00519532 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00519532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00519532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2007
Completion date
May 31, 2009
Enrollment
84 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease